Abstract Introduction and Objective The risks and benefits of medication use in pregnancy
are typically established through post-marketing observational studies. As there is currently …

Background Since the presence of a birth defect is often a primary outcome in drug‐safety
studies among pregnant women, researching the validity of data collection methods is …

Aims An increasing number of women trust the Internet for information about medication
safety during pregnancy. This study aimed to evaluate the availability and accuracy of social …

Background Information regarding the risk of early pregnancy COVID‐19 vaccination on the
development of major congenital anomalies in the offspring is still limited. Here, we study the …

Although marketing authorisation holders (MAHs) are involved in monitoring medication
safety, it was unclear how they experience their role and current monitoring activities in …

Aims Recent population‐based data on drug utilization around pregnancy are lacking. This
study aims to examine the prevalence of drug exposure in the Netherlands during the …

A Teratology Information Service (TIS) does not exist in Belgium yet but will hopefully be
established soon. To prepare for this, we aimed to provide insight into the information needs …

Although medication use during pregnancy is common, most available products lack
sufficient safety information. As prospective data collection and perinatal …

To assess the risk of exposure to a medicinal product during pregnancy in an individual
case report, the necessary information should be present, complete and clearly described …

Purpose Preeclampsia is a leading cause of maternal morbidity and mortality. Calcium-
based antacids and proton pump inhibitors (PPIs) are commonly used during pregnancy to …